# EDGAR Filing Document

**Accession Number:** 0001859803
**File Stem:** 0001628280-26-023150
**Filing Date:** 2026-4
**Character Count:** 7127
**Document Hash:** 7b8e05da90205b6e2400070def2a57f6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-023150.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001628280-26-023150

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Falcione Aaron
- **CENTRAL INDEX KEY:** 0001859803

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40235
- **FILM NUMBER:** 26833571

**MAIL ADDRESS:**
- **STREET 1:** 2000 GALLOPING HILL ROAD
- **CITY:** KENILWORTH
- **STATE:** NJ
- **ZIP:** 07033
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Organon & Co.
- **CENTRAL INDEX KEY:** 0001821825
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464838035
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 30 HUDSON STREET
- **STREET 2:** FL 33
- **CITY:** JERSEY CITY
- **STATE:** NJ
- **ZIP:** 07302
- **BUSINESS PHONE:** 551-430-6000

**MAIL ADDRESS:**
- **STREET 1:** 30 HUDSON STREET
- **STREET 2:** FL 33
- **CITY:** JERSEY CITY
- **STATE:** NJ
- **ZIP:** 07302

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Falcione Aaron<br><sub>(Last) (First) (Middle)</sub><br>C/O ORGANON & CO.<br>30 HUDSON STREET, FLOOR 33<br><sub>(Street)</sub><br>JERSEY CITY, NJ 07302<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Human Resources Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Organon & Co. [ OGN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-31 |  | M |  | 6732 | A | $0 | 96378.071 | D |  |
| Common Stock | 2026-03-31 |  | F |  | 2306 | D | 5.70<sup>(1)</sup> | 94072.071 | D |  |
| Common Stock | 2026-03-31 |  | M |  | 11193 | A | $0 | 105265.071 | D |  |
| Common Stock | 2026-03-31 |  | F |  | 3834 | D | 5.70<sup>(1)</sup> | 101431.071 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(2)</sup> | 2026-03-31 |  | A |  | 166944 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 166944 | $0 | 166944 | D |  |
| Restricted Stock Units | <sup>(3)</sup> | 2026-03-31 |  | M |  |  | 6732 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 6732 | $0 | 0 | D |  |
| Restricted Stock Units | <sup>(3)</sup> | 2026-03-31 |  | M |  |  | 11193 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 11193 | $0 | 22386 | D |  |

---

### Footnotes:

(1) The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

(2) On March 31, 2026, the Reporting Person was granted 166,944 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

(3) Each RSU represents a contingent right to receive one share of Organon common stock.

(4) On March 31, 2023, the Reporting Person was granted 20,195 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

(5) On March 31, 2025, the Reporting Person was granted 33,579 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining to vest on March 31, 2027 and March 31, 2028.

**Signature:** /s/ Tarnetta V. Jones, as Attorney-in-Fact for Aaron Falcione  
**Date:** 2026-04-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**